Literature DB >> 18422961

Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Francisco A Durazo1, Lawrence M Blatt, William G Corey, Jiing-Huey Lin, Steven Han, Sammy Saab, Ronald W Busuttil, Myron J Tong.   

Abstract

BACKGROUND AND AIM: Hepatocellular carcinoma (HCC) is a common complication in patients with chronic viral hepatitis. Detection of HCC at an early stage is critical for a favorable clinical outcome. The study aim was to: (i) compare the levels of des-gamma-carboxyprothrombin (DCP), alpha-fetoprotein (AFP) and AFP-L3 in HCC patients and in chronic viral hepatitis patients without HCC; (ii) define the level of each tumor marker with the best sensitivity and specificity for HCC diagnosis; and (iii) to correlate the levels of these markers with respect to size and tumor burden.
METHODS: Two hundred and forty patients with either hepatitis B virus (HBV) or hepatitis C virus (HCV) infection were studied. These included 144 with HCC, 47 with chronic hepatitis (fibrosis stage I-III on liver biopsy) and 49 with cirrhosis.
RESULTS: Levels of DCP, AFP and AFP L-3 were significantly higher in patients with HCC than in those without HCC (P < or = 0.0001). Receiver-operating curves (ROC) indicated that the cut-off value with the best sensitivity and specificity for each test was > or =84 mAU/mL for DCP, > or =25 ng/mL for AFP and > or =10% for AFP-L3. The sensitivity, specificity and positive predictive value (PPV) for DCP was 87%, 85% and 86.8%, for AFP 69%, 87% and 69.8%, and for AFP-L3 56%, 90% and 56.1%, respectively. DCP levels were below the ROC cut-off in all patients without HCC. In patients with single lesions, there was a direct correlation of DCP to tumor size. High levels of AFP correlated with diffuse type of HCC. All three markers were significantly elevated in the presence of metastatic HCC. No advantage was observed by combining two or three markers for HCC diagnosis.
CONCLUSION: DCP had the highest sensitivity and PPV for HCC diagnosis, had a direct correlation with tumor size, and was not elevated in any patients without HCC. DCP should be used as the main serum test for HCC detection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422961     DOI: 10.1111/j.1440-1746.2008.05395.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  62 in total

1.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 2.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

3.  Surveillance for hepatocellular carcinoma: in whom and how?

Authors:  Hashem B El-Serag; Jessica A Davila
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

4.  Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients.

Authors:  Shaogui Wan; Hie-Won Hann; Zhong Ye; Richard S Hann; Yinzhi Lai; Chun Wang; Ling Li; Ronald E Myers; Bingshan Li; Jinliang Xing; Hushan Yang
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

5.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Yukio Kume; Hitoshi Ikeda; Gary L Norman; Zakera Shums; Taku Aoki; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  J Gastroenterol       Date:  2010-07-13       Impact factor: 7.527

Review 6.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

7.  Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Seung In Seo; Hyoung Su Kim; Won Jin Kim; Woon Geon Shin; Doo Jin Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Joo Seop Kim; Hak Yang Kim; Dong Joon Kim; Myung Seok Lee; Choong Kee Park
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

8.  Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.

Authors:  Hideto Suzuki; Kazumoto Murata; Takaya Gotoh; Masao Kusano; Hiroshi Okano; Takashi Oyamada; Yoshikazu Yasuda; Masatoshi Imamura; Masatoshi Kudo; Masashi Mizokami; Atsushi Sakamoto
Journal:  J Gastroenterol       Date:  2011-07-09       Impact factor: 7.527

Review 9.  Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches.

Authors:  Jianhui Zhu; Elisa Warner; Neehar D Parikh; David M Lubman
Journal:  Mass Spectrom Rev       Date:  2018-11-25       Impact factor: 10.946

10.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Authors:  Jong Young Choi; Seung Won Jung; Hee Yeon Kim; Myungshin Kim; Yonggoo Kim; Dong Goo Kim; Eun-Jee Oh
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.